Pasithea Therapeutics Return On Equity vs. Current Valuation

KTTA Stock  USD 5.06  0.20  3.80%   
Based on Pasithea Therapeutics' profitability indicators, Pasithea Therapeutics Corp may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in July. Profitability indicators assess Pasithea Therapeutics' ability to earn profits and add value for shareholders.
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
(0.68)
Current Value
(0.65)
Quarterly Volatility
0.18151169
 
Credit Downgrade
 
Yuan Drop
 
Covid
As of June 29, 2024, Price To Sales Ratio is expected to decline to 36.39. In addition to that, Days Sales Outstanding is expected to decline to 181.32. At present, Pasithea Therapeutics' Total Other Income Expense Net is projected to increase significantly based on the last few years of reporting. The current year's Income Tax Expense is expected to grow to about 476.6 M, whereas Accumulated Other Comprehensive Income is forecasted to decline to (4.9 K).
For Pasithea Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pasithea Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pasithea Therapeutics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pasithea Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pasithea Therapeutics Corp over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(13.74)
Revenue Per Share
0.37
Quarterly Revenue Growth
14.981
Return On Assets
(0.33)
Return On Equity
(0.55)
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Pasithea Therapeutics Current Valuation vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Pasithea Therapeutics's current stock value. Our valuation model uses many indicators to compare Pasithea Therapeutics value to that of its competitors to determine the firm's financial worth.
Pasithea Therapeutics Corp is rated fifth overall in return on equity category among its peers. It is rated below average in current valuation category among its peers . At present, Pasithea Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pasithea Therapeutics' earnings, one of the primary drivers of an investment's value.

Pasithea Current Valuation vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Pasithea Therapeutics

Return On Equity

 = 

Net Income

Total Equity

 = 
-0.55
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Pasithea Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
(6.49 M)
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Pasithea Current Valuation vs Competition

Pasithea Therapeutics Corp is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about (24.48 Million). Pasithea Therapeutics has negative current valuation of (6.49 Million) having no influence on the industry.

Pasithea Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Pasithea Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pasithea Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Pasithea Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Pasithea Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-4.7 K-4.9 K
Operating Income-16 M-15.2 M
Income Before Tax-15.5 M-14.7 M
Total Other Income Expense Net471.6 K737.1 K
Net Loss-2 M-1.9 M
Net Loss-15.5 M-14.7 M
Income Tax Expense453.9 M476.6 M
Net Interest Income242.4 K254.6 K
Net Loss-16.7 M-17.6 M
Interest Income415.4 K228.5 K
Change To Netincome-1 M-1.1 M
Net Loss(13.01)(13.66)
Income Quality 0.87  1.19 
Net Income Per E B T 1.03  0.79 

Pasithea Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Pasithea Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pasithea Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pasithea Therapeutics' important profitability drivers and their relationship over time.

Use Pasithea Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pasithea Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pasithea Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Pasithea Therapeutics Pair Trading

Pasithea Therapeutics Corp Pair Trading Analysis

The ability to find closely correlated positions to Pasithea Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pasithea Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pasithea Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pasithea Therapeutics Corp to buy it.
The correlation of Pasithea Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pasithea Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pasithea Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pasithea Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Pasithea Therapeutics position

In addition to having Pasithea Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Long/short ETFs Thematic Idea Now

Long/short ETFs
Long/short ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Long/short ETFs theme has 23 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long/short ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Pasithea Stock

When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:
Check out Correlation Analysis.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
To fully project Pasithea Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Pasithea Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Pasithea Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Pasithea Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Pasithea Therapeutics investors may work on each financial statement separately, they are all related. The changes in Pasithea Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pasithea Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.